Silent hypersensitivity to Escherichia coli asparaginase in children with acute lymphoblastic leukemia

Leukemia and Lymphoma

Volumn 51, Issue 8, 2010, Pages 1464-1472

  Strullu, Marion ^a   Corradini, Nadège ^a   Audrain, Marie ^b   Orsonneau, Jean Luc ^b   Bouige, Daniel ^c   Thomare, Patrick ^d   Vermot Desroches, Claudine ^e   Mansuy, Adeline ^e   Legrand, Arnaud ^a   Rozé, Jean Christophe ^a   Mohty, Mohamad ^a,f   Méchinaud, Françoise ^a  

^a Hopital Mere Enfant CHU de Nantes   (France)

^b HÔTEL DIEU   (France)

^c LE HAVRE HOSPITAL   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

^e EUSA Pharma   (France)

^f UNIVERSITÉ DE NANTES   (France)

Author keywords

Allergy and hypersensitivity; lymphoid leukemia; the humoral immune response

Indexed keywords

ASPARAGINASE; ASPARAGINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ENZYME ANTIBODY; ETOPOSIDE; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; TIOGUANINE; VINCRISTINE; VINDESINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; AMINO ACID BLOOD LEVEL; ANAPHYLACTIC SHOCK; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FEMALE; GENETIC ANALYSIS; HUMAN; HYPERSENSITIVITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; LEUKOCYTE COUNT; MALE; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT OUTCOME; URTICARIA;

EID: 77955437646     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.494316     Document Type: Article

References (33)

1. Oettgen HF, Old LJ, Boyse EA, et al. Inhibition of leukemias in man by L-asparaginase. Cancer Res 1967;27:2619-2631.
2. Sallan SE, Hitchcock-Bryan S, Gelber R, Cassady JR, Frei E 3rd, Nathan DG. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res 1983;43:5601-5607.
3. Haley EE, Fischer GA, Welch AD. The requirement for Lasparagine of mouse leukemia cells L5178Y in culture. Cancer Res 1961;21:532-536.
4. Hawkins DS, Park JR, Thomson BG, et al. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia. Clin Cancer Res 2004;10:5335-5341.
5. Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 2002;99:1986-1994.
6. Armstrong JK, Hempel G, Koling S, et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 2007;110:103-111.
7. Woo MH, Hak LJ, Storm MC, et al. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia 1998;12:1527-1533.
8. Woo MH, Hak LJ, Storm MC, et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol 2000;18:1525-1532.
9. Panosyan EH, Seibel NL, Martin-Aragon S, et al. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J Pediatr Hematol Oncol 2004;26: 217-226.
10. Zalewska-Szewczyk B, Andrzejewski W, Mlynarski W, Jedrychowska- Danska K, Witas H, Bodalski J. The anti-asparagines antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia. Leuk Lymphoma 2007;48:931-936.
11. Killander D, Dohlwitz A, Engstedt L, et al. Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia. Cancer 1976;37:220-228.
12. Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993;11:1780-1786.
13. Capizzi RL, Bertino JR, Skeel RT, et al. L-asparaginase: clinical, biochemical, pharmacological, and immunological studies. Ann Intern Med 1971;74:893-901.
14. Larson RA, Fretzin MH, Dodge RK, Schiffer CA. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia 1998;12:660-665.
15. Wang B, Hak LJ, RellingMV, Pui CH,Woo MH, Storm MC. ELISA to evaluate plasma anti-asparaginase IgG concentrations in patients with acute lymphoblastic leukemia. J Immunol Methods 2000;239:75-83.
16. Orsonneau JL, Brassart EA, LecameM, Thomare P, Delaroche O, Dudouet D. Automated kinetic assay of plasmatic Lasparaginase activity undergoing therapy for acute lymphoblastic leukemia. Ann Biol Clin (Paris) 2004;62:568-572.
17. Boos J, Werber G, Ahlke E, et al. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer 1996;32A:1544-1550.
18. Land VJ, Sutow WW, Fernbach DJ, et al. Toxicity of L-asparginase in children with advanced leukemia. Cancer 1972;30:339-347.
19. Jacquillat C, Weil M, Bussel A, et al. Treatment of acute leukemia with L-asparaginase-preliminary results on 84 cases. Recent Results Cancer Res 1970;33:263-278.
20. Evans WE, Tsiatis A, Rivera G, et al. Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma. Cancer 1982;49:1378-1383.
21. Cheung NK, Chau IY, Coccia PF. Antibody response to Escherichia coli L-asparaginase. Prognostic significance and clinical utility of antibody measurement. Am J Pediatr Hematol Oncol 1986;8:99-104.
22. Nesbit M, Chard R, Evans A, et al. Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia. Am J Pediatr Hematol Oncol 1979;1:9-13.
23. Jaffe N, Traggis D, Das L, et al. L-asparaginase in the treatment of neoplastic diseases in children. Cancer Res 1971;31:942-949.
24. Lei Y, PanettaYang L, Panetta JC, et al. Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol 2008;26:1932-1939.
25. Muller HJ, Beier R, Loning L, et al. Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment. Br J Haematol 2001;114:794-799.
26. Ahlke E, Nowak-Gottl U, Schulze-Westhoff P, et al. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia. Br J Haematol 1997;96:675-681.
27. Albertsen BK, Schrøder H, Ingerslev J, et al. Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system. Br J Haematol 2001;115:983-990.
28. RiccardiR, Holcenberg JS, Glaubiger DL, et al. L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res 1981;41:4554-4558.
29. Appel IM, Pinheiro JP, den Boer ML, et al. Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL. Leukemia 2003;17:2254-2256.
30. Jarrar M, Gaynon PS, Periclou AP, et al. Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941). Pediatr Blood Cancer 2006;47:141-146.
31. Albertsen BK, Schrøder H, Jakobsen P, Müller HJ, Carlsen NT, Schmiegelow K. Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries. Br J Clin Pharmacol 2001;52:433-437.
32. Iwamoto S, Mihara K, Downing JR, Pui CH, Campana D. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest 2007;117: 1049-1057.
33. Hak LJ, Relling MV, Cheng C, Pei D, Wang B, Sandlund JT. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia. Leukemia 2004;18:1072-1077.